Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.11T
Market cap1.11T
Price-Earnings ratio
41.47
Price-Earnings ratio41.47
Dividend yield
0.53%
Dividend yield0.53%
Average volume
3.17M
Average volume3.17M
High today
$1,207.80
High today$1,207.80
Low today
$1,171.20
Low today$1,171.20
Open price
$1,196.02
Open price$1,196.02
Volume
2.11M
Volume2.11M
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$655.10
52 Week low$655.10

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,181.00, giving the company a market capitalization of 1.11T. It carries a P/E multiple of 41.47 and pays a dividend yield of 0.53%.

On 2026-08-14, Eli Lilly(LLY) stock traded between a low of $1,171.20 and a high of $1,207.80. Shares are currently priced at $1,181.00, which is +0.8% above the low and -2.2% below the high.

The Eli Lilly(LLY)'s current trading volume is 2.11M, compared to an average daily volume of 3.17M.

During the past year, Eli Lilly(LLY) stock moved between $655.10 at its lowest and $1,249.45 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $655.10 at its lowest and $1,249.45 at its peak.

LLY News

TipRanks 4h
Eli Lilly’s New Phase 1 Study Signals Ongoing Pipeline Expansion

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

TipRanks 4h
Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

The Motley Fool 6h
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool

...

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

More LLY News

Simply Wall St 8h
Eli Lilly Files Six Lawsuits Over Illicit Retatrutide Sales

Eli Lilly (NYSE: LLY) has launched a legal crackdown on illicit U.S. sales of its experimental obesity drug retatrutide, which is not approved for any use. The...

Eli Lilly Files Six Lawsuits Over Illicit Retatrutide Sales
Investor's Business Daily 8h
Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains

IBD Big Cap 20 Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains Licensing Eli Lilly (LLY) is the Big Cap 20 component in focus this week, as the stoc...

Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
Nasdaq 1d
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity

Key Points Eli Lilly has faced spotty insurance coverage for its GLP-1 medicines in the weight-loss market. However, lower realized prices are driving substan...

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
The Motley Fool 1d
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NVO -0.91%) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the compan...

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
TipRanks 1d
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly

Novo Nordisk (NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly (LLY) over what it alleges is false advertising...

TipRanks 1d
Novo Nordisk Stock Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly

Shares in Danish drugmaker Novo Nordisk (NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters...

Nasdaq 2d
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales

(RTTNews) - Eli Lilly (LLY) on Wednesday filed six lawsuits against U.S. companies it accused of illegally selling unauthorized versions of its experimental obe...

Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.